CA3013845C - METHODS FOR THE TREATMENT OF THE PIK3CA-RELATED OVERGROWTH SPECTRUM - Google Patents
METHODS FOR THE TREATMENT OF THE PIK3CA-RELATED OVERGROWTH SPECTRUMInfo
- Publication number
- CA3013845C CA3013845C CA3013845A CA3013845A CA3013845C CA 3013845 C CA3013845 C CA 3013845C CA 3013845 A CA3013845 A CA 3013845A CA 3013845 A CA3013845 A CA 3013845A CA 3013845 C CA3013845 C CA 3013845C
- Authority
- CA
- Canada
- Prior art keywords
- pros
- byl719
- overgrowth
- pik3ca
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Spectrometry And Color Measurement (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305193.1 | 2016-02-19 | ||
| EP16305193 | 2016-02-19 | ||
| PCT/EP2017/053587 WO2017140828A1 (en) | 2016-02-19 | 2017-02-17 | Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3013845A1 CA3013845A1 (en) | 2017-08-24 |
| CA3013845C true CA3013845C (en) | 2024-09-17 |
Family
ID=55409795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3013845A Active CA3013845C (en) | 2016-02-19 | 2017-02-17 | METHODS FOR THE TREATMENT OF THE PIK3CA-RELATED OVERGROWTH SPECTRUM |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11433059B2 (enExample) |
| EP (1) | EP3416642A1 (enExample) |
| JP (3) | JP7051693B2 (enExample) |
| KR (1) | KR20180115297A (enExample) |
| CN (3) | CN109562103A (enExample) |
| AU (3) | AU2017219834B2 (enExample) |
| CA (1) | CA3013845C (enExample) |
| WO (1) | WO2017140828A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296390A (en) * | 2015-05-15 | 2022-11-01 | Memorial Sloan Kettering Cancer Center | Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations |
| CN109562103A (zh) | 2016-02-19 | 2019-04-02 | 国家医疗保健研究所 | 用于治疗pik3ca相关过度生长综合征群的方法 |
| KR20210124310A (ko) | 2019-02-06 | 2021-10-14 | 벤테라, 인코포레이티드 | 국소 포스포이노시티드 3-키나제 억제제 |
| WO2025045915A1 (en) * | 2023-08-29 | 2025-03-06 | Institut National de la Santé et de la Recherche Médicale | Methods for inducing muscle hypertrophy |
| WO2025045129A1 (zh) * | 2023-08-30 | 2025-03-06 | 广州嘉越医药科技有限公司 | 化合物用于治疗pros谱系疾病的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008027013A2 (en) * | 2006-08-29 | 2008-03-06 | National Cancer Centre | Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| UA118846C2 (uk) * | 2013-03-21 | 2019-03-25 | Новартіс Аг | Комбінована терапія |
| IL296390A (en) * | 2015-05-15 | 2022-11-01 | Memorial Sloan Kettering Cancer Center | Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations |
| CN109562103A (zh) | 2016-02-19 | 2019-04-02 | 国家医疗保健研究所 | 用于治疗pik3ca相关过度生长综合征群的方法 |
-
2017
- 2017-02-17 CN CN201780011659.9A patent/CN109562103A/zh active Pending
- 2017-02-17 JP JP2018543362A patent/JP7051693B2/ja active Active
- 2017-02-17 EP EP17705872.4A patent/EP3416642A1/en active Pending
- 2017-02-17 KR KR1020187026976A patent/KR20180115297A/ko not_active Ceased
- 2017-02-17 US US15/998,950 patent/US11433059B2/en active Active
- 2017-02-17 WO PCT/EP2017/053587 patent/WO2017140828A1/en not_active Ceased
- 2017-02-17 CN CN202410563611.0A patent/CN118477076A/zh active Pending
- 2017-02-17 CA CA3013845A patent/CA3013845C/en active Active
- 2017-02-17 CN CN202410562274.3A patent/CN118477075A/zh active Pending
- 2017-02-17 AU AU2017219834A patent/AU2017219834B2/en active Active
-
2022
- 2022-01-31 JP JP2022012963A patent/JP2022058800A/ja active Pending
- 2022-04-14 US US17/721,067 patent/US12427141B2/en active Active
- 2022-09-21 AU AU2022235569A patent/AU2022235569B2/en active Active
-
2024
- 2024-07-04 JP JP2024107982A patent/JP2024125429A/ja active Pending
- 2024-12-19 AU AU2024278598A patent/AU2024278598A1/en active Pending
-
2025
- 2025-05-16 US US19/210,131 patent/US20250339417A1/en active Pending
- 2025-06-04 US US19/227,991 patent/US20250295645A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022235569A1 (en) | 2022-10-13 |
| AU2024278598A1 (en) | 2025-01-16 |
| US20250295645A1 (en) | 2025-09-25 |
| WO2017140828A1 (en) | 2017-08-24 |
| AU2017219834A1 (en) | 2018-08-23 |
| KR20180115297A (ko) | 2018-10-22 |
| JP7051693B2 (ja) | 2022-04-11 |
| EP3416642A1 (en) | 2018-12-26 |
| AU2022235569B2 (en) | 2024-10-10 |
| US20250339417A1 (en) | 2025-11-06 |
| CN118477076A (zh) | 2024-08-13 |
| US20200215044A1 (en) | 2020-07-09 |
| US11433059B2 (en) | 2022-09-06 |
| JP2019505549A (ja) | 2019-02-28 |
| US20220323428A1 (en) | 2022-10-13 |
| CN109562103A (zh) | 2019-04-02 |
| US12427141B2 (en) | 2025-09-30 |
| JP2024125429A (ja) | 2024-09-18 |
| AU2017219834B2 (en) | 2022-06-30 |
| CN118477075A (zh) | 2024-08-13 |
| CA3013845A1 (en) | 2017-08-24 |
| JP2022058800A (ja) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022235569B2 (en) | BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome) | |
| Luo et al. | Perfect match: mTOR inhibitors and tuberous sclerosis complex | |
| EP3498278B1 (en) | Compounds for treatment of diseases related to dux4 expression | |
| US11723911B2 (en) | Treatment of demyelinating diseases | |
| Zhang et al. | Mechanical stress regulates autophagic flux to affect apoptosis after spinal cord injury | |
| Wang et al. | Microglia-derived TNF-α contributes to RVLM neuronal mitochondrial dysfunction via blocking the AMPK–Sirt3 pathway in stress-induced hypertension | |
| CN108289870A (zh) | 治疗特定患者群体的神经变性病症的方法 | |
| Cao et al. | Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury | |
| Quinn et al. | Effects of dantrolene therapy on disease phenotype in dystrophin deficient mdx mice | |
| Hayes et al. | Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse | |
| RU2716164C2 (ru) | Стабильные композиции нейроактивных пептидов | |
| WO2020068719A1 (en) | Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia | |
| TW202519221A (zh) | Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合 | |
| WO2024128311A1 (ja) | 脈管奇形用医薬組成物及び脈管奇形の治療方法 | |
| Bonnard et al. | Macrophage Neutrophil Gelatinase-Associated Lipocalin Has a Critical Role in Aldosterone-Induced Renal Fibrosis via the CCL5-IL4 Pathway: PO2129 | |
| Cheofor et al. | Altered Tryptophan Catabolism via the Kynurenine Pathway Associates with CKD-Accelerated Atherosclerosis: PO2131 | |
| WO2025125788A1 (en) | Sabizabulin for use in the treatment of polycystic kidney disease | |
| Brackhan | Investigation of brain inflammation as a nuclear imaging biomarker of epileptogenesis and a treatment target for epilepsy prevention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |
|
| EEER | Examination request |
Effective date: 20220119 |